{"id":"anti-pd-1-checkpoint-inhibitor","safety":{"commonSideEffects":[{"rate":"3-4%","effect":"Pneumonitis"},{"rate":"1-2%","effect":"Colitis"},{"rate":"10-20%","effect":"Hypothyroidism"}]},"_chembl":{"chemblId":"CHEMBL4297953","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"PD-1 inhibitors block the PD-1 receptor on T cells, preventing its interaction with PD-L1 and allowing the immune system to attack cancer cells.","oneSentence":"Inhibits PD-1 receptor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:10:06.631Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Melanoma"}]},"trialDetails":[{"nctId":"NCT04840589","phase":"PHASE1","title":"Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-02","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma","enrollment":66},{"nctId":"NCT03017820","phase":"PHASE1","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-04-04","conditions":"B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome","enrollment":127},{"nctId":"NCT04995523","phase":"PHASE1, PHASE2","title":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-09-14","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":212},{"nctId":"NCT07488533","phase":"PHASE2","title":"Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-01","conditions":"Non-Clear Cell Renal Cell Carcinoma","enrollment":40},{"nctId":"NCT04387084","phase":"PHASE1","title":"Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2020-08-12","conditions":"Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm","enrollment":10},{"nctId":"NCT07487519","phase":"PHASE2","title":"Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-04-25","conditions":"Breast Cancer (Triple Negative Breast Cancer (TNBC))","enrollment":180},{"nctId":"NCT07403136","phase":"PHASE2","title":"Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-02-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":52},{"nctId":"NCT06173505","phase":"PHASE1, PHASE2","title":"Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC","status":"TERMINATED","sponsor":"Xencor, Inc.","startDate":"2023-12-27","conditions":"Nonsquamous Non-small Cell Lung Cancer","enrollment":28},{"nctId":"NCT05364086","phase":"","title":"An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Rochester NCORP Research Base","startDate":"2022-04-26","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":2100},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT06989112","phase":"PHASE3","title":"DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-27","conditions":"Endometrial Cancer","enrollment":600},{"nctId":"NCT05824481","phase":"PHASE2","title":"Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-05-08","conditions":"Endometrial Cancer, Endometrial Adenocarcinoma","enrollment":32},{"nctId":"NCT05824468","phase":"PHASE2","title":"Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-05-10","conditions":"Cervical Cancer, Cervical Carcinoma","enrollment":30},{"nctId":"NCT06821503","phase":"PHASE1, PHASE2","title":"Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-11","conditions":"Advanced Pancreatic Cancer","enrollment":72},{"nctId":"NCT06975293","phase":"PHASE1, PHASE2","title":"STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers","status":"RECRUITING","sponsor":"STORM Therapeutics LTD","startDate":"2025-05-05","conditions":"Metastatic Non-small Cell Lung Cancer, Metastatic Melanoma, Metastatic Endometrial Cancer","enrollment":188},{"nctId":"NCT06857279","phase":"PHASE2","title":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-04-22","conditions":"Carcinoma of Head and/or Neck","enrollment":167},{"nctId":"NCT07452003","phase":"NA","title":"An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-01-03","conditions":"Non-Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT07205731","phase":"PHASE2","title":"Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2025-10-07","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":95},{"nctId":"NCT06545955","phase":"PHASE3","title":"A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Ferring Pharmaceuticals","startDate":"2024-10-01","conditions":"Non-muscle Invasive Bladder Cancer With Carcinoma in Situ","enrollment":250},{"nctId":"NCT04969887","phase":"PHASE2","title":"Combination Immunotherapy in Rare Cancers Under InvesTigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Olivia Newton-John Cancer Research Institute","startDate":"2021-08-03","conditions":"Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm","enrollment":240},{"nctId":"NCT05329766","phase":"PHASE2","title":"A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2022-06-10","conditions":"Gastrointestinal Tract Malignancies","enrollment":332},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT07335497","phase":"PHASE1, PHASE2","title":"CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Crescent Biopharma, Inc.","startDate":"2026-02-17","conditions":"Locally Advanced / Metastatic Solid Tumors","enrollment":290},{"nctId":"NCT06581406","phase":"PHASE2, PHASE3","title":"A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-12-17","conditions":"Metastatic Uveal Melanoma","enrollment":280},{"nctId":"NCT04041310","phase":"PHASE1, PHASE2","title":"Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nouscom SRL","startDate":"2019-10-21","conditions":"Solid Tumor, Adult","enrollment":115},{"nctId":"NCT04080804","phase":"PHASE2","title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2019-12-20","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":80},{"nctId":"NCT03789110","phase":"PHASE2","title":"NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-03-08","conditions":"Breast Cancer","enrollment":30},{"nctId":"NCT07385989","phase":"PHASE2","title":"Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"WEI XU","startDate":"2026-01-25","conditions":"Extranodal NK/T-cell Lymphoma","enrollment":40},{"nctId":"NCT06710847","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-12-13","conditions":"Neoplasms, Colorectal, Solid Tumor, Colon Cancer","enrollment":14},{"nctId":"NCT07379489","phase":"","title":"Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2026-01-31","conditions":"HCC, Adjuvant Therapy, Recurrence","enrollment":300},{"nctId":"NCT06283238","phase":"","title":"Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON)","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2025-04-16","conditions":"GastroEsophageal Cancer","enrollment":""},{"nctId":"NCT06599619","phase":"","title":"Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi","status":"RECRUITING","sponsor":"John Kirkwood","startDate":"2025-02-20","conditions":"Melanoma","enrollment":30},{"nctId":"NCT02819752","phase":"PHASE1","title":"PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck","status":"TERMINATED","sponsor":"Royal Marsden NHS Foundation Trust","startDate":"2017-07-12","conditions":"Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma","enrollment":3},{"nctId":"NCT06006923","phase":"PHASE2","title":"Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer","status":"TERMINATED","sponsor":"Anwaar Saeed","startDate":"2024-06-26","conditions":"MSI-H Colorectal Cancer","enrollment":1},{"nctId":"NCT06470971","phase":"PHASE2","title":"Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial","status":"RECRUITING","sponsor":"Yuanquan Yang","startDate":"2024-07-09","conditions":"Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm","enrollment":40},{"nctId":"NCT07348107","phase":"PHASE1","title":"ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Daniel Breadner","startDate":"2026-02-15","conditions":"Advanced Pancreatic Ductal Adenocarcinoma","enrollment":10},{"nctId":"NCT05529316","phase":"PHASE2","title":"A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agenus Inc.","startDate":"2022-12-12","conditions":"Advanced Melanoma","enrollment":150},{"nctId":"NCT07231458","phase":"PHASE1","title":"A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies","status":"RECRUITING","sponsor":"Abalos Therapeutics GmbH","startDate":"2025-10-14","conditions":"Advanced Solid Tumors","enrollment":27},{"nctId":"NCT03228667","phase":"PHASE2","title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-12-11","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma","enrollment":40},{"nctId":"NCT04725474","phase":"PHASE1, PHASE2","title":"First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CatalYm GmbH","startDate":"2020-12-09","conditions":"Solid Tumor, Adult","enrollment":263},{"nctId":"NCT05777603","phase":"PHASE1","title":"Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-18","conditions":"Advanced Non Small Cell Lung Cancer","enrollment":23},{"nctId":"NCT06295159","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-05-17","conditions":"Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma","enrollment":90},{"nctId":"NCT04526899","phase":"PHASE2","title":"A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2021-05-19","conditions":"Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma","enrollment":184},{"nctId":"NCT06265727","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors","status":"RECRUITING","sponsor":"Corbus Pharmaceuticals Inc.","startDate":"2024-04-01","conditions":"Solid Tumor, Adult","enrollment":348},{"nctId":"NCT06393361","phase":"PHASE2","title":"Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-06-01","conditions":"Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma","enrollment":100},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT03993379","phase":"PHASE2","title":"PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors","status":"TERMINATED","sponsor":"CytomX Therapeutics","startDate":"2019-11-20","conditions":"Solid Tumor, Unresectable or Metastatic Melanoma","enrollment":3},{"nctId":"NCT03388632","phase":"PHASE1","title":"Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-05","conditions":"Metastatic Solid Tumors, Treatment-Refractory Cancers","enrollment":31},{"nctId":"NCT04688658","phase":"PHASE1, PHASE2","title":"Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma","status":"TERMINATED","sponsor":"John Kirkwood","startDate":"2021-10-06","conditions":"Unresectable Melanoma","enrollment":13},{"nctId":"NCT05733598","phase":"PHASE2","title":"Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-08-01","conditions":"Hepatocellular Carcinoma, Biliary Tract Cancer","enrollment":60},{"nctId":"NCT06794775","phase":"PHASE3","title":"SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma","status":"RECRUITING","sponsor":"Hildur Helgadottir","startDate":"2025-07-10","conditions":"Malignant Melanoma Stage III","enrollment":128},{"nctId":"NCT04916002","phase":"PHASE2","title":"A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-11-30","conditions":"Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma","enrollment":77},{"nctId":"NCT04248569","phase":"PHASE1","title":"DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-04-20","conditions":"Fibrolamellar Hepatocellular Carcinoma (FLC)","enrollment":56},{"nctId":"NCT03767582","phase":"PHASE1, PHASE2","title":"Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-12-12","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Ductal Adenocarcinoma","enrollment":46},{"nctId":"NCT03307785","phase":"PHASE1","title":"Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042","status":"COMPLETED","sponsor":"Tesaro, Inc.","startDate":"2017-10-12","conditions":"Neoplasms, Metastatic Cancer, Advanced Cancer","enrollment":60},{"nctId":"NCT07238881","phase":"PHASE2","title":"Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-11-05","conditions":"Hepatocellulcar Carcinoma","enrollment":30},{"nctId":"NCT05389514","phase":"","title":"Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors","status":"TEMPORARILY_NOT_AVAILABLE","sponsor":"Providence Health & Services","startDate":"","conditions":"KRAS G12V Mutant Advanced Epithelial Cancers","enrollment":""},{"nctId":"NCT07240194","phase":"PHASE2","title":"The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-09-01","conditions":"Large B-cell Lymphoma, TP53","enrollment":24},{"nctId":"NCT02936102","phase":"PHASE1","title":"A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-10-20","conditions":"Advanced Solid Tumors, Triple Negative Breast Cancer, Chordoma and Alveolar Soft Part Sarcoma","enrollment":154},{"nctId":"NCT05935748","phase":"PHASE2","title":"Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)","status":"TERMINATED","sponsor":"NiKang Therapeutics, Inc.","startDate":"2023-07-28","conditions":"ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer","enrollment":18},{"nctId":"NCT05271318","phase":"PHASE1, PHASE2","title":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.","status":"RECRUITING","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2022-05-17","conditions":"Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma","enrollment":29},{"nctId":"NCT05205330","phase":"PHASE1, PHASE2","title":"Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rottapharm Biotech","startDate":"2021-11-23","conditions":"Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer","enrollment":107},{"nctId":"NCT05597839","phase":"PHASE1, PHASE2","title":"Study of DF9001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2022-11-15","conditions":"Solid Tumor, Adult","enrollment":24},{"nctId":"NCT03901573","phase":"PHASE1, PHASE2","title":"High-Risk Skin Cancers With Atezolizumab Plus NT-I7","status":"TERMINATED","sponsor":"NeoImmuneTech","startDate":"2019-12-26","conditions":"Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma","enrollment":31},{"nctId":"NCT03906071","phase":"PHASE3","title":"Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Mirati Therapeutics Inc.","startDate":"2019-07-15","conditions":"Metastatic Non-Squamous Non-Small Cell Lung Cancer","enrollment":577},{"nctId":"NCT05453799","phase":"PHASE2","title":"Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2022-07-21","conditions":"Locally Advanced Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Oncocytic Carcinoma","enrollment":54},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT06188208","phase":"PHASE1","title":"A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vividion Therapeutics, Inc.","startDate":"2024-01-05","conditions":"Advanced Solid Tumors, Advanced Hematologic Tumors","enrollment":125},{"nctId":"NCT04631601","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"TERMINATED","sponsor":"Amgen","startDate":"2021-01-15","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":65},{"nctId":"NCT06463665","phase":"PHASE2","title":"Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2024-09-26","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":142},{"nctId":"NCT05271604","phase":"PHASE2","title":"A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"BioAtla, Inc.","startDate":"2022-12-13","conditions":"Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck","enrollment":42},{"nctId":"NCT04681131","phase":"PHASE2","title":"CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC","status":"COMPLETED","sponsor":"BioAtla, Inc.","startDate":"2021-03-17","conditions":"Non-Small-Cell Lung Cancer","enrollment":85},{"nctId":"NCT03425279","phase":"PHASE1, PHASE2","title":"CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma","status":"COMPLETED","sponsor":"BioAtla, Inc.","startDate":"2018-02-15","conditions":"Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma","enrollment":245},{"nctId":"NCT04047186","phase":"PHASE2","title":"Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules","status":"COMPLETED","sponsor":"XiangNing Fu","startDate":"2019-07-01","conditions":"Multiple Pulmonary Nodules","enrollment":12},{"nctId":"NCT04577807","phase":"PHASE2","title":"LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma","status":"COMPLETED","sponsor":"Istari Oncology, Inc.","startDate":"2020-11-17","conditions":"Melanoma","enrollment":27},{"nctId":"NCT07070479","phase":"PHASE2","title":"Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-06-24","conditions":"Recurrent or Metastatic Nasopharyngeal Carcinoma","enrollment":208},{"nctId":"NCT03108495","phase":"PHASE2","title":"Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma","status":"TERMINATED","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2017-06-22","conditions":"Cervical Carcinoma","enrollment":210},{"nctId":"NCT05733351","phase":"PHASE1","title":"Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer","status":"TERMINATED","sponsor":"Emory University","startDate":"2023-08-03","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":4},{"nctId":"NCT04546399","phase":"PHASE2","title":"A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-12-17","conditions":"Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia","enrollment":461},{"nctId":"NCT07007182","phase":"PHASE2","title":"Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jinbo Yue","startDate":"2025-10-01","conditions":"Gastric Adenocarcinoma, Stomach Neoplasms","enrollment":54},{"nctId":"NCT05509699","phase":"PHASE2","title":"Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2022-09-27","conditions":"Extensive-Stage Small Cell Lung Cancer","enrollment":21},{"nctId":"NCT04047862","phase":"PHASE1","title":"Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-08-15","conditions":"Locally Advanced and Metastatic Solid Tumors","enrollment":446},{"nctId":"NCT07134413","phase":"PHASE2","title":"QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Association of Clinical Trials","startDate":"2025-08","conditions":"NSCLC","enrollment":77},{"nctId":"NCT03708328","phase":"PHASE1","title":"A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-10-15","conditions":"Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC)","enrollment":134},{"nctId":"NCT07130032","phase":"PHASE2","title":"Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade","status":"RECRUITING","sponsor":"EuroCityClinic LLC","startDate":"2025-08-14","conditions":"Metastatic Non-small Cell Lung Cancer (NSCLC), Metastatic Cutaneous Melanoma","enrollment":90},{"nctId":"NCT03170960","phase":"PHASE1","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2017-09-05","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":914},{"nctId":"NCT07100405","phase":"","title":"TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-08-15","conditions":"Hepatocellular Carcinoma","enrollment":50},{"nctId":"NCT02879695","phase":"PHASE1","title":"Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-10-25","conditions":"Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia","enrollment":28},{"nctId":"NCT04225039","phase":"PHASE2","title":"Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2020-06-23","conditions":"Glioblastoma","enrollment":39},{"nctId":"NCT07113964","phase":"PHASE2","title":"QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-08-30","conditions":"Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency","enrollment":79},{"nctId":"NCT06896422","phase":"PHASE1","title":"Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2025-06-01","conditions":"Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody","enrollment":80},{"nctId":"NCT04046133","phase":"PHASE1","title":"Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cardiff University","startDate":"2020-10-19","conditions":"Anal Cancer Stage III A, Anal Cancer Stage III B","enrollment":52},{"nctId":"NCT02903914","phase":"PHASE1","title":"Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-09-14","conditions":"Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC)","enrollment":260},{"nctId":"NCT07022002","phase":"PHASE2","title":"SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors","status":"RECRUITING","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2025-07-30","conditions":"Locally Advanced, Recurrent or Metastatic Malignancies","enrollment":340},{"nctId":"NCT04306900","phase":"PHASE1","title":"TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers","status":"COMPLETED","sponsor":"Trishula Therapeutics, Inc.","startDate":"2020-03-30","conditions":"Solid Tumor, Adult","enrollment":185},{"nctId":"NCT04879368","phase":"PHASE3","title":"RegoNivo vs Standard of Care Chemotherapy in AGOC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2021-06-01","conditions":"Gastro-Oesophageal Cancer","enrollment":450},{"nctId":"NCT07068178","phase":"PHASE2","title":"Evaluating the Efficacy of Hyperthermic Intraperitoneal Treatment to Enhance the Sensitivity of Immune Checkpoint Inhibitor in Patients With Advanced Ovarian Cancer： A Single-arm Study","status":"NOT_YET_RECRUITING","sponsor":"Jing Li","startDate":"2025-08","conditions":"HIPEC, Ovarian Serous Adenocarcinoma","enrollment":30},{"nctId":"NCT04493203","phase":"PHASE2","title":"Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma","status":"COMPLETED","sponsor":"Yana Najjar","startDate":"2020-12-18","conditions":"Advanced Melanoma, Unresectable Melanoma","enrollment":31},{"nctId":"NCT05086692","phase":"PHASE1, PHASE2","title":"A Beta-only IL-2 ImmunoTherapY Study","status":"RECRUITING","sponsor":"Medicenna Therapeutics, Inc.","startDate":"2021-08-27","conditions":"Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma","enrollment":115},{"nctId":"NCT07049185","phase":"PHASE2","title":"QL1706 Plus Celecoxib in Advanced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-07-15","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Anti-PD-1 Checkpoint Inhibitor","genericName":"Anti-PD-1 Checkpoint Inhibitor","companyName":"Istari Oncology, Inc.","companyId":"istari-oncology-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Inhibits PD-1 receptor Used for Non-small cell lung cancer, Melanoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}